SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Solberg A)
 

Sökning: WFRF:(Solberg A) > Treatment of stage ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007774naa a2200841 4500
001oai:gup.ub.gu.se/240441
003SwePub
008240528s2016 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:3e3d6197-3796-4f8a-8790-eb4fe9ad479c
009oai:DiVA.org:liu-130658
009oai:prod.swepub.kib.ki.se:133952737
0247 a https://gup.ub.gu.se/publication/2404412 URI
0247 a https://doi.org/10.1093/annonc/mdw1642 DOI
0247 a https://lup.lub.lu.se/record/3e3d6197-3796-4f8a-8790-eb4fe9ad479c2 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1306582 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1339527372 URI
040 a (SwePub)gud (SwePub)lud (SwePub)liud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Tandstad, T.u St. Olav’s University Hospital,St Olavs University Hospital, Norway4 aut
2451 0a Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
264 1b Elsevier BV,c 2016
500 a Funding Agencies|Research Committee at St Olavs Hospital, Trondheim; Swedish Cancer Society; Swedish Association of Local Authorities and Regions; Norwegian Regional Health Authorities; Norwegian Urological Cancer Group
520 a A total of 1118 patients with clinical stage I seminoma one course of adjuvant carboplatin or managed by surveillance were included. Stromal invasion of rete testis and tumor size > 4 cm are confirmed as risk factors predicting relapse. Relapse rates following one course of adjuvant carboplatin is high and there is need to explore more effective adjuvant treatment options in patients with seminoma.The purpose of the protocol was to reduce the treatment burden in clinical stage I (CSI) seminoma by offering risk-adapted treatment. The protocol aimed to prospectively validate the proposed risk factors for relapse, stromal invasion of the rete testis and tumor diameter > 4 cm, and to evaluate the efficacy of one course of adjuvant carboplatin. From 2007 to 2010, 897 patients were included in a prospective, population-based, risk-adapted treatment protocol implementing one course of adjuvant carboplatin AUC7 (>n = 469) or surveillance (>n = 422). In addition, results from 221 patients receiving carboplatin between 2004 and 2007 are reported. At a median follow-up of 5.6 years, 69 relapses have occurred. Stromal invasion of the rete testis [hazard ratio (HR) 1.9, >P = 0.011] and tumor diameter > 4 cm (HR 2.7, >P < 0.001) were identified as risk factors predicting relapse. In patients without risk factors, the relapse rate (RR) was 4.0% for patients managed by surveillance and 2.2% in patients receiving adjuvant carboplatin. In patients with one or two risk factors, the RR was 15.5% in patients managed by surveillance and 9.3% in patients receiving adjuvant carboplatin. We found no increased RR in patients receiving carboplatin < 7 x AUC compared with that in patients receiving a parts per thousand yen7 x AUC. Stromal invasion in the rete testis and tumor diameter > 4 cm are risk factors for relapse in CSI seminoma. Patients without risk factors have a low RR and adjuvant therapy is not justified in these patients. The efficacy of adjuvant carboplatin is relatively low and there is need to explore more effective adjuvant treatment options in patients with high-risk seminoma. The data do not support the concept of a steep dose response for adjuvant carboplatin.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng
653 a testicular cancer
653 a seminoma
653 a surveillance
653 a adjuvant carboplatin
653 a risk-adapted
653 a prognostic factors
653 a germ-cell-cancer
653 a prognostic-factors
653 a relapse
653 a patterns
653 a Oncology
653 a Adjuvant carboplatin
653 a Prognostic factors
653 a Risk-adapted
653 a Seminoma
653 a Surveillance
653 a Testicular cancer
653 a testicular cancer; seminoma; surveillance; adjuvant carboplatin; risk-adapted; prognostic factors
7001 a Ståhl, Olofu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital, Sweden4 aut0 (Swepub:lu)kir-ost
7001 a Dahl, O.u University of Bergen, Norway; Haukeland Hospital, Norway4 aut
7001 a Haugnes, H. S.u University of Tromso, Norway; University Hospital North Norway, Norway4 aut
7001 a Håkansson, U.u Lund University,Lunds universitet,Urologi,Forskargrupper vid Lunds universitet,Urology,Lund University Research Groups,Skåne University Hospital, Sweden4 aut0 (Swepub:lu)kir-uha
7001 a Karlsdottir, A.u Haukeland University Hospital,Haukeland Hospital, Norway4 aut
7001 a Kjellman, A.u Karolinska Institutet4 aut
7001 a Langberg, C. W.u Oslo University Hospital, Norway4 aut
7001 a Laurell, A.u University of Uppsala Hospital, Sweden4 aut0 (Swepub:lu)med-al21
7001 a Oldenburg, J.u Akershus University Hospital, Norway; University of Oslo, Norway4 aut
7001 a Solberg, A.u St. Olav’s University Hospital,St Olavs University Hospital, Norway4 aut
7001 a Söderström, K.u Norrland University Hospital, Sweden4 aut0 (Swepub:lu)kosu-kso
7001 a Stierner, Ulrika,d 1952u University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Sahlgrens University Hospital, Sweden; University of Gothenburg, Sweden4 aut0 (Swepub:gu)xstiul
7001 a Cavallin-Ståhl, E.u Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital, Sweden4 aut0 (Swepub:lu)onk-ecs
7001 a Wahlqvist, R.u Oslo University Hospital, Norway4 aut
7001 a Wall, Najmeu Linköpings universitet,Avdelningen för kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US4 aut0 (Swepub:liu)najwa86
7001 a Cohn-Cedermark, G.u Karolinska Institutet,Karolinska Institute,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden4 aut
7102 a St. Olav’s University Hospitalb St Olavs University Hospital, Norway4 org
7730 t Annals of Oncologyd : Elsevier BVg 27:7, s. 1299-1304q 27:7<1299-1304x 0923-7534x 1569-8041
8564 u https://doi.org/10.1093/annonc/mdw164
8564 u http://dx.doi.org/10.1093/annonc/mdw164y FULLTEXT
8564 8u https://gup.ub.gu.se/publication/240441
8564 8u https://doi.org/10.1093/annonc/mdw164
8564 8u https://lup.lub.lu.se/record/3e3d6197-3796-4f8a-8790-eb4fe9ad479c
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-130658
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:133952737

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy